Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer

Pathobiology

Volumn 76, Issue 1, 2009, Pages 30-38

  Ishida, Eiwa ^a   Nakamura, Mitsutoshi ^a   Shimada, Keiji ^a   Tasaki, Masato ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen receptor; Calcitonin; Immunohistochemistry; Neuroendocrine cells; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CALCITONIN; NEUROPEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; ATROPHY; BIOCHEMISTRY; CELL PROLIFERATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GLEASON SCORE; HORMONAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE SYSTEM; NEUROSECRETORY CELL; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SAMPLE;

ADENOCARCINOMA; AGED; CALCITONIN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOGRANIN A; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NEUROSECRETORY SYSTEMS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 59649093542     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178153     Document Type: Article

References (34)

1. Delellis RA, Dayal Y: The neuroendocrine system;in Mills SE (ed): Histology for Pathologists, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2007, pp s1189-s1210.
2. Huang J, Yao JL, di Sant'Agnese PA: Neuroendocrine differentiation in prostate cancer; in Kirby RS, Partin AW, Feneley MR, Parsons JK (eds): Prostate Cancer, Principles and Practice. New York, Taylor & Francis, 2006, pp 143-150.
3. Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V, Hansson J, Helboe L, Abrahamsson PA: Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 2002;7:91-98.
4. Wu G, Burzon DT, di Sant'Agnese PA, Schoen S, Deftos LJ, Gershagen S, Cockett AT: Calcitonin receptor mRNA expression in the human prostate. Urology 1996;47:376-381.
5. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L: Peptide-hormone-and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298-307.
6. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R: Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999;162:1800-1805.
7. Bonkhoff H, Remberger K: Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98-106.
8. Larran J, Salido M, Aparicio J, Lopez A, de Palacio ML, Vilches J: In vitro characterization of bombesin and calcitonin on the proliferation of PC3, Du 145 and LNCaP cancer prostatic cell lines. Int J Dev Biol 1996;suppl 1:275S-276S.
9. Sun B, Halmos G, Schally AV, Wang X, Martinez M: Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 2000;42:295-303.
10. Tovar Sepulveda VA, Falzon M: Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept 2002;105:109-120.
11. Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE: Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997;31:183-192.
12. Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC, Nanus DM: Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin Cancer Res 2002;8:2399-2405.
13. Weinstein MH, Partin AW, Veltri RW, Epstein JI: Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27:683-687.
14. Bollito E, Berruti A, Bellina M, Mosca A, Leonardo E, Tarabuzzi R, Cappia S, Ari MM, Tampellini M, Fontana D, Gubetta L, Angeli A, Dogliotti L: Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 2001;12(suppl 2):S159-S164.
15. Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V, Linke J, Siegsmund M, May M: Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 2008;26:243-250.
16. Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJ, Schroder FH: The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252-258.
17. Steineck G, Reuter V, Kelly WK, Frank R, Schwartz L, Scher HI: Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 2002;41:668-674.
18. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C: Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992;147:798-803.
19. Konishi N, Tsujikawa K, Yamamoto H, Ishida E, Nakamura M, Shimada K, Yane K, Yamashita H, Noguchi S: Overexpression of leukocyte common antigen (LAR) P-subunit in thyroid carcinoma. Br J Cancer 2003;88:1223-1228.
20. De Marzo AM, Marchi VL, Epstein JI, Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-1992.
21. Faith D, Han S, Lee DK, Friedl A, Hicks JL, De Marzo AM, Jarrard DF: P16 is upregulated in proliferative inflammatory atrophy of the prostate. Prostate 2005;65:73-82.
22. Putzi MJ, De Marzo AM: Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000;56:828-832.
23. Untergasser G, Plas E, Pfister G, Heinrich E, Berger P: Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells. Prostate 2005;64:419-429.
24. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC: Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007;67:764-773.
25. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI, Berman DM: Roles for the stem cell associated intermediate filament nestin in prostate cancer migration and metastasis. Cancer Res 2007;67:9199-9206.
26. di Sant'Agnese PA, de Mesy Jensen KL: Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1987;18:849-856.
27. Asadi F, Farraj M, Sharifi R, Malakouti S, Antar S, Kukreja S: Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol 1996;27:1319-1323.
28. Bostwick DG, Dousa MK, Crawford BG, Wollan PC: Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 1994;18:1240-1246.
29. Jongsma J, Oomen MH, Noordzij MA, Romijn JC, van Der Kwast TH, Schroder FH, van Steenbrugge GJ: Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 2000;42:34-44.
30. Chigurupati S, Kulkarni T, Thomas S, Shah G: Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. Cancer Res 2005;65:8519-8529.
31. Sabbisetti VS, Chiruqupati S, Thomas S, Vaidya KS, Reardon D, Chriva-Internati M, Iczkowski KA, Shah GV: Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP dependent protein kinase A in calcitonin action. Int J Cancer 2005;117:551-560.
32. Thomas S, Chriva-Internati M, Shah GV: Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling. Clin Exp Metastasis 2007;24:363-377.
33. Theodoropoulos VE, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris AC, Patsouris E, Ghikonti I: Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005;66:897-902.
34. Sadi MV, Walsh PC, Barrack ER: Immunohistochemical study of androgen receptors in metastatic prostate cancer: comparison of receptor content and response to hormonal therapy. Cancer 1991;67:3057-3064.